Abzena to humanise antibodies for CAR T cell therapies

Abzena Plc is to apply its antibody technology to chimeric antigen receptor (CAR) T cell development under a new agreement with Tmunity Therapeutics Inc, a company co-founded by Carl June, head of the scientific team that discovered Kymriah.